Dr. Laura Hall -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Laura Hall, a Internal Medicine physician based in Boston, MA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Laura Hall has received $34,212.74 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Laura Hall
- Medical Specialty: Internal Medicine
- Practice Location: Boston, MA, Massachusetts
- NPI Number: 1968764612
- Transparency Score: 50/100
- Payment Records Span: 2025-11-12 to 2025-11-12
Payment Summary
Dr. Laura Hall has received a total of $34,212.74 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $34,212.74 per transaction.
- Total Payments Received: $34,212.74
- Number of Transactions: 1
- Average Payment: $34,212.74
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Laura Hall's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Speaking & Education | $34,212.74 | Promotional speaking, CME events, and educational presentations |
The largest payment category for Dr. Laura Hall is Speaking & Education, accounting for 100% ($34,212.74) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Laura Hall. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Pfizer Inc | $34,212.74 | 1 |
Dr. Laura Hall has a financial relationship with Pfizer Inc, receiving $34,212.74 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Laura Hall. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Mounjaro -- Referenced in payment records from pharmaceutical companies to Dr. Laura Hall
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Laura Hall's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Laura Hall, an Internal Medicine specialist in Boston, MA, has a pharmaceutical payment profile characterized by a single, substantial payment. With a total of $34,212.74 received from pharmaceutical companies, this amount is significantly higher than the typical payment volume for physicians in Internal Medicine. The vast majority, if not all, of this total stems from a relationship with Pfizer Inc., amounting to $34,212.74. This singular relationship and payment amount suggest a focused engagement with one company, rather than a broad network of interactions. The payment was categorized as 'speaking,' scheduled for November 12, 2025. This indicates a payment for educational or informational services provided by Dr. Hall to Pfizer, likely related to their products or research. The nature of this payment, a speaking engagement, is a common form of professional interaction between physicians and pharmaceutical companies. However, the substantial amount associated with this single event warrants consideration. While speaking engagements can be a legitimate way for physicians to share their expertise and stay abreast of medical advancements, a large payment for a single event could raise questions about potential influence. For patients, understanding these relationships is crucial. It doesn't automatically imply that a doctor's medical judgment is compromised, but it does highlight a financial connection that could, consciously or unconsciously, shape perspectives on treatments. Patients should view this profile as a piece of information to consider alongside their doctor's overall care, communication style, and treatment recommendations. Transparency in these financial dealings allows patients to have more informed conversations with their healthcare providers about all factors influencing their care.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Laura Hall is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When reviewing your doctor's financial relationships with pharmaceutical companies, it's important to maintain perspective. A single, large payment, like Dr. Hall's speaking engagement with Pfizer, is a notable data point but doesn't automatically indicate compromised care. Normal professional activities include receiving payments for speaking, consulting, or participating in research, which helps disseminate medical knowledge. However, a pattern of numerous large payments, especially for activities like meals or travel, or a lack of transparency about these relationships, could be a red flag. At your next appointment, consider asking your doctor general questions like, 'Are you involved in any research or speaking engagements with pharmaceutical companies?' or 'How do you stay updated on the latest treatments and medications?' This can open a dialogue. Evaluate your doctor's prescribing patterns by discussing why certain medications are recommended, their alternatives, and potential side effects. If you have concerns, research the medications prescribed and discuss them openly. Ultimately, trust is built on open communication and a doctor's consistent demonstration of prioritizing patient well-being above all else.
Peer Comparison: How Dr. Laura Hall Compares to Other Internal Medicine Physicians
The average total payments for Internal Medicine physicians typically range from a few hundred to a few thousand dollars annually, often spread across multiple smaller transactions. Dr. Hall's single payment of $34,212.74 significantly exceeds this average. While some specialists may receive higher payments for research or consulting, a payment of this magnitude for a single speaking engagement is notably high for the specialty.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Laura Hall in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Pfizer Inc | $34,212.74 | speaking | Mounjaro | 2025-11-12 | Not Assessed |
Frequently Asked Questions About Dr. Laura Hall's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Laura Hall taking too much pharma money?
Dr. Hall received a single payment of $34,212.74 from Pfizer for a speaking engagement. While this amount is significantly higher than the average total payments for Internal Medicine physicians, it represents one transaction. The key is the context: a single speaking engagement, while substantial, is a recognized form of professional interaction. It's crucial to consider this alongside her overall practice and patient outcomes rather than solely on the payment amount.
What pharma companies pay Dr. Laura Hall?
Dr. Laura Hall received payments exclusively from Pfizer Inc., totaling $34,212.74. This indicates a singular financial relationship with this pharmaceutical company.
Should I switch doctors because of pharma payments?
A pharma payment alone is not usually a reason to switch doctors. Consider the nature and volume of payments. A single, large payment for a speaking engagement, as in Dr. Hall's case, is less concerning than a pattern of numerous small payments for meals or travel, or undisclosed conflicts of interest. Focus on your doctor's communication, treatment recommendations, and whether you feel your health is their priority.
What kinds of payments does this doctor receive?
Dr. Hall received one payment totaling $34,212.74, which was specifically for a 'speaking' engagement with Pfizer Inc. This means the payment was likely for her expertise in discussing medical topics, potentially related to Pfizer's products or research, during an event.
How do these payments compare to other Internal Medicine?
Dr. Hall's total payment of $34,212.74 from a single speaking engagement is substantially higher than the typical annual payment volume for Internal Medicine physicians, which often ranges from a few hundred to a few thousand dollars. This single payment is an outlier compared to the average peer profile.
Do pharma payments affect prescribing quality?
Research suggests that even small payments can subtly influence physician prescribing habits. However, the extent of this influence varies greatly. While a payment doesn't automatically mean a doctor will prescribe inappropriately, it highlights a potential bias. Patients should discuss treatment choices openly with their doctor and consider evidence-based guidelines.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website, search for Dr. Laura Hall using her NPI (1968764612), and review the detailed records of payments made to her by pharmaceutical and medical device companies.
Understanding This Doctor Payment Report
This transparency report for Dr. Laura Hall is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Laura Hall's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Laura Hall and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- Massachusetts Physician Payments -- Browse pharmaceutical payments to physicians in Massachusetts
- Internal Medicine Physicians in Massachusetts -- Compare Dr. Laura Hall to peers in the same state and specialty
- Pfizer Inc Payment Profile -- View all payments made by Dr. Laura Hall's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Laura Hall's NPI (1968764612) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.